What is a stock summary page? Click here for an overview.
Business Description
Qualigen Therapeutics Inc
NAICS : 541713
SIC : 8731
ISIN : US74754R2022
Share Class Description:
QLGN: Ordinary SharesDescription
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.27 | |||||
| Equity-to-Asset | -0.93 | |||||
| Debt-to-Equity | -0.67 | |||||
| Debt-to-EBITDA | -0.21 | |||||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -28.3 | |||||
| 3-Year EPS without NRI Growth Rate | -20.9 | |||||
| 3-Year FCF Growth Rate | -165 | |||||
| 3-Year Book Growth Rate | 38.2 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 89.16 | |||||
| 9-Day RSI | 78.42 | |||||
| 14-Day RSI | 67.8 | |||||
| 3-1 Month Momentum % | -24.12 | |||||
| 6-1 Month Momentum % | -62.54 | |||||
| 12-1 Month Momentum % | -83.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.52 | |||||
| Quick Ratio | 0.52 | |||||
| Cash Ratio | 0.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -62.4 | |||||
| Shareholder Yield % | 26.7 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -385.04 | |||||
| ROIC % | -257.82 | |||||
| 3-Year ROIIC % | 455.97 | |||||
| ROC (Joel Greenblatt) % | -358.14 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.52 | |||||
| EV-to-EBITDA | -0.52 | |||||
| EV-to-Forward-Revenue | 0.01 | |||||
| EV-to-FCF | -0.36 | |||||
| Earnings Yield (Greenblatt) % | -192.31 | |||||
| FCF Yield % | -349.41 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:QLGN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Qualigen Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -285.848 | ||
| Beta | 0.03 | ||
| 3-Year Sharpe Ratio | -2.71 | ||
| 3-Year Sortino Ratio | -2.29 | ||
| Volatility % | 62.45 | ||
| 14-Day RSI | 67.8 | ||
| 14-Day ATR ($) | 0.18476 | ||
| 20-Day SMA ($) | 3.17733 | ||
| 12-1 Month Momentum % | -83.8 | ||
| 52-Week Range ($) | 2.96 - 29.435 | ||
| Shares Outstanding (Mil) | 0.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Qualigen Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Qualigen Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Qualigen Therapeutics Inc Frequently Asked Questions
What is Qualigen Therapeutics Inc(QLGN)'s stock price today?
The current price of QLGN is $3.78. The 52 week high of QLGN is $29.44 and 52 week low is $2.96.
When is next earnings date of Qualigen Therapeutics Inc(QLGN)?
The next earnings date of Qualigen Therapeutics Inc(QLGN) is 2025-07-02 Est..
Does Qualigen Therapeutics Inc(QLGN) pay dividends? If so, how much?
Qualigen Therapeutics Inc(QLGN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers